| Summary: | The discovery of novel probiotic bacteria from free-ranging animals for the treatment of inflammatory bowel disease in domestic pets is a unique approach. The chloroform extraction of gastrointestinal (GI) tract material was used to inactivate vegetative cells and select for spore-forming bacteria. A bacterium identified as a novel <i>Paenibacillus</i> sp. strain via small ribosomal RNA (16S) gene sequencing was isolated from the GI tract of a gray wolf (<i>Canis lupus</i>). The bacterium was typed as Gram-variable, both catalase/oxidase-positive and positive via starch hydrolysis and lipase assays. The bacterium inhibited the growth of <i>Staphylococcus aureus, Escherichia coli</i> and <i>Micrococcus luteus</i>. The draft whole genome sequence (WGS) assembly was 7,034,206 bp in length, encoding 6543 genes, and is similar in size and coding capacity to other closely related <i>Paenibacillus</i> spp. The isolate’s genome encodes several germination and sporulation gene products along with antimicrobials such as a bacteriocin system and chitinase. Enzyme genes such as alpha amylase, cellulase, lipases and pectin lyase are also present in the genome. An incomplete lysogenic bacteriophage genome was also present in the isolate’s genome. Phenotypic characteristics combined with a WGS genotype analysis indicate that this bacterium, designated <i>Paenibacillus</i> sp. ClWae2A, could be a potential candidate probiotic for domestic dogs.
|
|---|